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Abstract 
Background: Using patient data from the GetGoal-Duo1, -L, and L-Asia trials, the objectives of this study were to 
evaluate and compare the impact of lixisenatide once-daily add-on treatment to basal insulin therapy ±oral antidia-
betic drugs (OADs) among type 2 diabetes (T2DM) patients subdivided into groups, based on their baseline body 
mass indices (BMI).
Methods: Data of patients treated with lixisenatide were extracted from the modified intent-to-treat populations 
of the trials. Patients were subdivided into 4 groups based on baseline BMI category (BMIs <25, 25–<30, 30–<35, and 
≥35 kg/m2). At the unadjusted data level, efficacy and safety endpoints were evaluated and compared among study 
cohorts. Additionally, multivariable regression analyses were used to specify key patient characteristics and then 
assess the adjusted outcomes.
Results: Of the 662 T2DM patients, the mean changes in HbA1c (−0.63 to −0.73 %, p = 0.88) and FPG levels (−3.9 
to 3.2 mg/dL, p = 0.60) were not significantly different among the different BMI groups. The proportions of T2DM 
patients that achieved HbA1c <7 % ranged between 34.7 and 46.8 %. After adjusted for patient characteristics, T2DM 
patients in the lowest BMI group relative to those in the highest BMI group had a smaller reduction in HbA1c during 
the trial periods (difference: 0.32 %, confidence interval: 0.10, 0.53, p = 0.005) and were less likely to achieve HbA1c 
<7 %.
Conclusions: The findings of this analysis of the GetGoal clinical trials suggest that lixisenatide may be a good treat-
ment option for optimizing glycemic control in patients unable to achieve their HbA1c target on basal insulin therapy 
±OADs, regardless of BMI category.
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Background
Type 2 diabetes mellitus (T2DM) is a metabolic dis-
ease resulting from insulin resistance and β-cell dys-
function, both of which worsen over time. It is not rare 
that the progression of T2DM requires the addition of 
other treatments to diet, exercise, or oral antidiabetic 
drugs (OADs). The addition of basal insulin therapy can 
improve glycemic control [1, 2]. However, different from 
fasting hyperglycemia, postprandial hyperglycemia is not 
well controlled with basal insulin therapy and may be 
the limiting factor for achieving optimal glycemic con-
trol for many T2DM patients [3, 4]. Other detriments of 
basal insulin therapy include risks for hypoglycemia and 
weight gain [2].
Lixisenatide is a glucagon-like peptide-1 (GLP-1) 
receptor agonist, of which its antidiabetic actions are pri-
marily attributed to the stimulation of glucose-dependent 
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insulin secretion via direct action on β cells [2]. Lixisena-
tide also delays gastric emptying and promotes satiety, 
thereby stimulating weight loss [2]. In addition, lixisena-
tide suppresses glucagon secretion, which accompanied 
with the delay in gastric emptying and the increase in 
β-cell glucose sensitivity contributes to a marked reduc-
tion in postprandial glucose (PPG) level [2, 5–7]. These 
features of lixisenatide make it a practical option in con-
junction with basal insulin therapy, which contributes 
primarily to lowering fasting plasma glucose (FPG).
The efficacy and safety of lixisenatide treatment for 
T2DM were evaluated in the GetGoal clinical trial pro-
gram comprised of 11 trials [2]. GetGoal-Duo1, Get-
Goal-L, and GetGoal-L-Asia evaluated the efficacy and 
safety of lixisenatide add-on treatment to basal insulin 
therapy ±OADs among patients with T2DM [5–7]. In 
the GetGoal-Duo1 trial; add-on treatment to basal insu-
lin plus metformin alone or in combination with other 
OADs, and in the GetGoal-L trial; add-on treatment to 
basal insulin ±metformin, they were associated with sig-
nificant reductions in HbA1c (mean difference: −0.3  %; 
p  <  0.0001 and −0.4  %; p  =  0.0002), PPG (2  h after a 
standardized meal test, mean difference: −57.6  mg/
dL, p  <  0.0001 and −68.4  mg/dL, p  <  0.0001), and 
body weight (mean difference: −0.9 kg, p =  0.0012 and 
−1.3 kg, p < 0.0001), respectively, relative to placebo add-
on treatment [5, 6]. In the GetGoal-L-Asia trial; add-on 
treatment to basal insulin ±sulfonylurea, it was associ-
ated with significant reductions in HbA1c (mean differ-
ence: −0.88  %; p  <  0.0001) and PPG (mean difference: 
−140.9 mg/dL, p < 0.0001) and a trend for reduction in 
body weight (mean change: −0.38 kg, p =  0.0857) rela-
tive to placebo add-on treatment [7].
A study of the relationship between body mass index 
(BMI) and disease risk using two national surveys, 
NHANES and SHIELD, observed that increased BMI is 
a predictor of increased prevalence of diabetes as already 
known [8]. In particular, this study reported that while 
>75 % of patients with diabetes are overweight or obese, 
between 10 and 25  % are not overweight [8]. Further-
more, obesity-related diseases, including T2DM, occur at 
lower BMIs among persons in Asian countries [9]. It is 
therefore important to evaluate the efficacy and safety of 
antidiabetic treatments in the context of BMI subcatego-
ries. Using data from the GetGoal-Duo1, -L, and -L-Asia 
trials, the objectives of this study were to evaluate and 
compare the impact of lixisenatide once-daily add-
on treatment to basal insulin therapy  ±  OADs among 
T2DM patients placed in different BMI categories at the 




All modified intent-to-treat patients from the GetGoal-
Duo1 (NCT00975286), -L (NCT00715624), and -L-Asia 
(NCT00866658) trials with baseline and endpoint HbA1c 
measurements and baseline BMI measurements were 
included in the analysis. All three trials evaluated within 
the intent-to-treat populations the efficacy and safety of 
lixisenatide add-on treatment to basal insulin therapy 
±OADs vs. placebo [5–7]. The primary efficacy outcome 
was the absolute change in HbA1c from baseline to week 
24 [5–7]. In the trials lixisenatide treatment consisted of a 
once-daily injection in a two-step dose-increase regimen 
(10 μg for 1 week, 15 μg for 1 week, and then 20 μg if tol-
erated) [5–7]. All trials were approved by the institutional 
review boards or ethics committees and were conducted 
in accordance with the principles of the Declaration of 
Helsinki and Good Clinical Practice guidelines. Further 
details of the trials can be found in each individual study 
publication [5–7]. For this analysis patients from all three 
trials who were originally randomized to lixisenatide 
add-on treatment to basal insulin therapy ±OADs were 
subdivided into 4 groups based on their baseline BMI 
category (BMIs <25, 25–<30, 30–<35, and ≥35 kg/m2).
Demographics and clinical characteristics
Demographics and key patient clinical characteristics, 
including baseline BMI, body weight, HbA1c, FPG, PPG 
(standardized 2-h meal test), and basal insulin dose and 
durations of T2DM, OAD use, and insulin use were 
determined based on clinical trial data.
Efficacy and safety outcomes
Efficacy outcomes included mean changes in baseline 
to endpoint measurements in HbA1c, BMI, weight, 
FPG, and PPG. Additionally, the proportions of T2DM 
patients in the different BMI groups that achieved and 
did not achieve HbA1c <7 % and FPG <110 mg/dL were 
determined. The safety outcomes for evaluation included 
the proportions of T2DM patients in the different BMI 
groups that experienced severe and symptomatic hypo-
glycemia (requiring blood glucose levels <60 mg/dL) dur-
ing trial periods. Other outcomes evaluated during the 
trial periods included the proportions of T2DM patients 
in the different BMI groups that achieved the following 
composite endpoints: HbA1c <7 % and no symptomatic 
hypoglycemia, HbA1c <7  % and no severe hypoglyce-
mia, HbA1c <7 % and no weight gain, HbA1c <7 % and 
no symptomatic hypoglycemia and no weight gain, and 
HbA1c <7 % and no severe hypoglycemia and no weight 
gain.
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Statistical analyses
Descriptive statistics were used to measure and describe 
patient demographics and clinical characteristics as well 
as the efficacy and safety outcome measurements. The 
study groups, defined by baseline BMI category, were 
compared to one another with p-values calculated using 
a χ2 test or ANOVA test where appropriate. A p value 
of 0.05 was used to determine the level of statistical 
significance.
Multivariable regression analyses
Multivariable regression analyses were used to assess the 
efficacy and safety outcomes, while adjusting key patient 
characteristics. Generalized linear models were used to 
examine whether there were differences in changes in 
HbA1c, FPG, PPG, and body weight among the different 
BMI study groups treated with lixisenatide add-on treat-
ment. Estimated differences, 95 % confidence limits, and 
p-values were reported. Logistic regressions were used 
to assess the relative odds of symptomatic hypoglycemia 
and of achieving composite endpoints among the dif-
ferent BMI study groups treated with lixisenatide add-
on treatment. Odds ratios, 95  % confidence limits, and 
p-values were reported. Covariates in all of the regression 
analyses included age, gender, and baseline FPG, PPG, 
HbA1c, and basal insulin dose/weight, and durations of 
diabetes, OAD use, and insulin use. All statistical analy-
ses were carried out using SAS® 9.3 (Cary, NC, USA).
Results
Characteristics of study population
Of the 662 T2DM patients treated with lixisenatide 
add-on treatment to basal insulin ±OADs included 
in this analysis, 133 (20 %), 222 (34 %), 166 (25 %), and 
141 (21  %) had a baseline BMI <25, 25–<30, 30–<35, 
and ≥35  kg/m2 respectively. Baseline characteristics of 
study groups are summarized in Table  1. Mean ages of 
study groups were not significantly different (range 56.5–
58.0 years, p = 0.58). Greater proportions of females vs. 
males were grouped in higher baseline BMI groups. The 
mean durations of OAD use (5.6–6.7 years, p = 0.29) and 
insulin use (1.7–2.3 years, p = 0.35) were similar among 
study groups. However, T2DM duration increased as 
BMI decreased (BMI <25 kg/m2: 13.1 years, 25–<30 kg/
m2: 12.4  years, 30–<35  kg/m2: 11.3  years, ≥35  kg/m2: 
10.4 years, p = 0.0043).
Efficacy of lixisenatide add‑on treatment to basal insulin 
therapy ±OADs
In Table  2, baseline, week 24, and mean changes from 
baseline to week 24 of efficacy measurements are summa-
rized for each BMI group of patients from the 3 GetGoal 
trials. The mean changes in HbA1c (−0.63 to −0.73  %, 
p = 0.88) and FPG levels (−3.9 to 3.2 mg/dL, p = 0.60) 
were not significantly different among the different 
BMI groups. At the unadjusted state, the mean reduc-
tions in PPG level increased as BMI decreased (BMI 
<25  kg/m2: −126.6  mg/dL, 25–<30  kg/m2: −103.5  mg/
dL, 30–<35 kg/m2: −82.0 mg/dL, ≥35 kg/m2: −67.2 mg/
dL, p < 0.0001). Greater baseline basal insulin doses were 
observed as BMI increased, but the mean changes in 
basal insulin doses over trial periods did not significantly 
differ among BMI groups (p  =  0.72). Mean changes in 
body weight (p = 0.06) and BMI (p = 0.07) did not reach 
the significance level among BMI groups.
The proportions of T2DM patients that achieved an 
HbA1c <7 % ranged between 34.7 and 46.8 % and trended 
(p = 0.09) to be greater for the higher BMI groups, but 
did not reach the significance level (Fig.  1b). The pro-
portions of T2DM patients in different BMI groups that 
Table 1 Baseline characteristics of study groups
BMI body mass index, SD standard deviation, OAD oral antidiabetic drug
* Statistical significance of differences was determined by ANOVA
** Statistical significance of differences was determined by X2  test
BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 P value
Total patient count, n (%) 133 (20 %) 222 (34 %) 166 (25 %) 141 (21 %)
Age (years), mean (SD) 57.2 (10.4) 58.0 (9.5) 57.3 (9.7) 56.5 (9.8) 0.58*
Gender 0.0495**
 Female, n (%) 62 (46.6) 117 (52.7) 88 (53.0) 89 (63.1)
 Male, n (%) 71 (53.4) 105 (47.3) 78 (47.0) 52 (36.9)
Baseline weight (kg), mean (SD) 61.0 (9.0) 73.8 (9.9) 88.9 (11.8) 110.4 (18.6) <0.0001*
Baseline BMI (kg/m2), mean (SD) 23.1 (1.5) 27.6 (1.5) 32.4 (1.4) 40.3 (5.0) <0.0001*
Diabetes duration (years), mean (SD) 13.1 (7.7) 12.4 (6.8) 11.3 (7.1) 10.4 (6.8) 0.0043*
OAD history (years), mean (SD) 5.9 (4.8) 6.4 (6.2) 6.7 (5.4) 5.6 (4.4) 0.29*
Insulin history (years), mean (SD) 2.3 (3.9) 2.2 (3.2) 1.7 (2.5) 1.9 (3.2) 0.35*
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achieved the evaluated composite endpoints also did 
not significantly differ, but trended to be greater for the 
higher BMI groups (Table 3).
Safety of lixisenatide add‑on treatment to basal insulin 
therapy ±OADs
The frequency of severe hypoglycemia was low for all 
BMI groups and did not significantly differ among the 
BMI groups (Table  4). The frequency of symptomatic 
hypoglycemia (requiring blood glucose level <60 mg/dL) 
ranged between 24.1 and 32.3 % and also did not signifi-
cantly differ among the BMI groups (Table 4).
Multivariable regression results
A summary of the significant multivariable regression 
results of T2DM patients treated with lixisenatide add-on 
treatment to basal insulin therapy ±OADs placed in dif-
ferent BMI groups is presented in Table 5. After adjusted 
for patient characteristics, T2DM patients in the lowest 
BMI group (<25 kg/m2) relative to the highest BMI group 
(≥35  kg/m2) had a smaller reduction in HbA1c during 
trial periods (difference: 0.32 %, CI 0.10, 0.53, p = 0.005). 
Changes in FPG, PPG, and body weight were not signifi-
cantly different among the different BMI study groups at 
the adjusted level. Also, the likelihood of symptomatic 
Table 2 Clinical responses of study groups to lixisenatide add-on treatment to basal insulin therapy ± oral antidiabetic 
drugs
BMI body mass index, FPG fasting plasma glucose, PPG postprandial blood glucose
Data are mean (SD = standard deviation) unless otherwise stated
a 2 h after a standardized meal test
* Statistical significance of differences was determined by ANOVA
** Statistical significance of differences was determined by χ2 test
Subgroups BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
HbA1c,  % (SD)
 Baseline 8.23 (0.81) 8.24 (0.82) 8.06 (0.92) 8.06 (0.84) 0.07*
 Week 24 7.61 (1.25) 7.56 (1.17) 7.38 (1.07) 7.33 (1.09) 0.10*
 Mean change from baseline −0.63 (1.19) −0.68 (1.08) −0.68 (0.92) −0.73 (0.92) 0.88*
Patients with endpoint HbA1c n (%) 0.09**
 <7 % 47 (35.3) 77 (34.7) 69 (41.6) 66 (46.8)
 ≥7 % 86 (64.7) 145 (65.3) 97 (58.4) 75 (53.2)
FPG mg/dL (SD)
 Baseline 129.2 (41.1) 133.7 (44.2) 136.5 (40.7) 137.7 (41.7) 0.35*
 Week 24 132.5 (46.9) 135.4 (54.2) 132.7 (42.5) 135.6 (45.3) 0.90*
 Mean change from baseline 3.2 (52.7) 1.7 (59.8) −3.9 (46.6) −2.1 (40.8) 0.60*
Patients with endpoint FPG n (%) 0.63**
 <110 mg/dL 48 (36.6) 81 (37.2) 54 (32.5) 44 (31.7)
 ≥110 mg/dL 83 (63.4) 137 (62.8) 112 (67.5) 95 (68.4)
PPG mg/dL (SD)a
 Baseline 301.5 (75.2) 287.5 (77.3) 279.0 (82.2) 252.6 (75.2) <0.0001*
 Week 24 175.0 (86.8) 184.7 (83.8) 197.3 (82.0) 185.5 (68.9) 0.15*
 Mean change from baseline −126.6 (109.7) −103.5 (109.2) −82.0 (103.1) −67.2 (84.0) <0.0001*
 Percent change from baseline −42 % −36 % −29 % −27 %
Basal insulin dose U (SD)
 Baseline 26.2 (11.6) 36.5 (15.5) 50.3 (24.8) 63.9 (41.2) <0.0001*
 Week 24 25.5 (12.1) 36.2 (17.0) 50.4 (26.1) 62.1 (31.6) <0.0001*
 Mean change from baseline −0.7 (4.8) −0.3 (6.8) 0.2 (10.0) −1.8 (29.8) 0.72*
Body weight kg (SD)
 Baseline 61.0 (9.0) 73.8 (9.9) 88.9 (11.8) 110.4 (18.6) <0.0001*
 Week 24 60.8 (9.3) 73.1 (10.0) 87.9 (12.2) 109.4 (19.1) <0.0001*
 Mean change from baseline −0.2 (2.0) −0.7 (2.4) −1.0 (3.3) −1.0 (3.5) 0.06*
BMI kg/m2 (SD)
 Baseline 23.1 (1.5) 27.6 (1.5) 32.4 (1.4) 40.3 (5.0)
 Week 24 23.1 (1.7) 27.4 (1.7) 32.0 (1.8) 39.9 (5.3) <0.0001*
 Mean change from baseline −0.1 (0.8) −0.2 (0.9) −0.4 (1.2) −0.4 (1.3) 0.07*
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hypoglycemia was similar among the different BMI 
groups treated with lixisenatide add-on treatment. 
T2DM patients in the lower BMI groups (<25  kg/m2, 
BMI 25–<30  kg/m2) relative to the highest BMI group 
(≥35  kg/m2) had lesser likelihoods of achieving HbA1c 
<7  % during trial periods (<25  kg/m2 OR 0.48, CI 0.27, 
0.86, p  =  0.014; BMI 25–<30  kg/m2 OR 0.59, CI 0.37, 
0.92, p = 0.020). Additionally, T2DM patients in the low-
est BMI group (<25  kg/m2) relative to the highest BMI 
group (≥35  kg/m2) had lesser likelihoods of achieving 
an HbA1c <7  % with no weight gain (OR 0.47, CI 0.26, 
0.88, p =  0.018) and of achieving an HbA1c <7  % with 
no severe hypoglycemia and no weight gain (OR 0.47, CI 
0.26, 0.88, p = 0.018) during trial periods.
Discussion
The results of this analysis demonstrate that lixisena-
tide once-daily add-on treatment to basal insulin ther-
apy ±OADs reduces HbA1c and PPG levels in T2DM 
patients across all BMI categories. The mean reductions 
in PPG levels were greater for T2DM patients catego-
rized in lower BMI groups, but after adjusted for other 
patient characteristics they were not significantly dif-
ferent from the other BMI groups. In regard to HbA1c 
levels, after the adjustment the mean reduction was 
smaller for T2DM patients of normal weight relative to 
severely obese T2DM patients. Additionally, those with 
Fig. 1 Mean Change in HbA1c of Study Groups (a) and Propor-
tions of Study Groups that Achieved an Endpoint HbA1c <7 % (b). 
Statistical significance of differences in mean changes in HbA1c was 
determined by ANOVA with standard error presented and that of the 
differences in the proportions of T2DM patients with an endpoint 
HbA1c <7 % was determined by χ2 test
Table 3 Frequency of achievement of composite endpoints among study groups
BMI body mass index; Statistical significance was determined by χ2 test
BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
HbA1c <7 % and no symptomatic hypoglycemia, n (%) 26 (19.6) 58 (26.1) 49 (29.5) 42 (29.8) 0.18
HbA1c <7 % and no severe hypoglycemia, n (%) 47 (35.3) 76 (34.2) 69 (41.6) 65 (46.1) 0.10
HbA1c <7 % and no weight gain, n (%) 31 (23.3) 54 (24.3) 48 (28.9) 49 (34.8) 0.10
HbA1c <7 %, no symptomatic hypoglycemia, and no weight 
gain, n (%)
16 (12.0) 42 (18.9) 36 (21.7) 29 (20.6) 0.16
HbA1c <7 %, no severe hypoglycemia, and no weight gain, 
n, (%)
31 (23.3) 54 (24.3) 48 (28.9) 48 (34.0) 0.14
Table 4 Frequency of hypoglycemia among study groups
SD standard deviation
a Requiring blood glucose <60 mg/dL
* Statistical significance of differences was determined by ANOVA
** Statistical significance of differences was determined by χ2 test
BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
Severe hypoglycemia, n (%) 1 (0.8) 2 (0.9) 0 (0.0) 2 (1.4) 0.54**
Events/patient-year mean (SD) 0.05 (0.6) 0.2 (3.5) 0.0 (0.0) 0.03 (0.3) 0.63*
Symptomatic hypoglycemiaa, n (%) 43 (32.3) 62 (27.9) 43 (25.9) 34 (24.1) 0.46**
Events/patient-year mean (SD) 2.2 (4.4) 2.1 (6.3) 1.8 (4.9) 1.6 (6.7) 0.81*
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greater obesity were more likely to achieve an HbA1c 
<7 %. Greater obesity also correlated with a lesser dura-
tion of T2DM. Although, in the subgroup of patients 
with BMI <25  kg/m2 there was a greater proportion of 
Asian patients, which may have in part influenced the 
assessment of the relationship between T2DM dura-
tion and BMI, the trend of decreasing T2DM duration 
with increasing of BMI was observed across all BMI sub-
groups. The potentially greater efficacy of lixisenatide 
add-on treatment among those with severe obesity may 
in part be attributed to a less progressed state of diabe-
tes. These observations may require further study for 
confirmation.
Lixisenatide treatment had a small effect on FPG level; 
however, this was expected as prior to initiating lixi-
senatide treatment, insulin therapy was stabilized and 
FPG levels were controlled among patients in the Get-
Goal trials [5–7]. Lixisenatide treatment was associated 
with a significant reduction in PPG levels, which led to 
better HbA1c control [5–7]. The relative contribution of 
postprandial hyperglycemia on overall glycemic control 
has been shown in other studies to contribute between 
70 and 80 % to overall glycemic exposure in patients with 
relatively good glycemic control and to contribute less 
(40  %) in patients with poor glycemic control [10, 11]. 
Riddle et al. reported that targeting postprandial hyper-
glycemia is more critical in T2DM patients on basal 
insulin therapy with HbA1c not at target, as it is the main 
contributor to hyperglycemic exposure [12, 13]. The sub-
stantial lowering of PPG level associated with lixisenatide 
treatment may also potentially provide a cardiovascular 
benefit [14–16]. The International Diabetes Federation 
has recognized the importance of PPG control in reduc-
ing cardiovascular disease risks, in addition to other 
diabetic complications, and recommended lowering of 
postprandial glycemia as a major focus of T2DM man-
agement [17]. Further results of the influence of lixisena-
tide on cardiovascular outcomes are expected in 2015 
after completion of the multicenter ELIXA study (Evalua-
tion of Cardiovascular Outcomes in Patients with Type 2 
Diabetes after Acute Coronary Syndrome During Treat-
ment with AVE0010 [Lixisenatide], NCT01147250) [18].
A patient’s BMI did not significantly influence the fre-
quency of hypoglycemia among lixisenatide treated 
patients. Hypoglycemia has been correlated with higher 
weight-based insulin doses in other studies, but this was 
not the case in this analysis [19]. In fact, among T2DM 
patients in higher BMI groups basal insulin doses were sig-
nificantly greater; however the frequency of symptomatic 
hypoglycemia trended to decrease as BMI increased. Also, 
large changes in insulin doses did not occur among the dif-
ferent BMI study groups treated with lixisenatide add-on 
treatment during trial periods, which may be attributed in 
part to the design of these GetGoal trials, such that basal 
Table 5 Summary of multivariable regression results of type 2 diabetes patients treated with lixisenatide add-on treat-
ment to basal insulin therapy ± oral antidiabetic drugs placed in different body mass index (BMI) groups based on their 
baseline BMI
Estimated difference 95 % Confidence limits P‑value
Lower Upper
Change in HbA1c (%)
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.32 0.10 0.53 0.005
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.09 −0.09 0.26 0.32
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 −0.01 −0.18 0.17 0.94
Odds ratio Lower Upper p‑value
Endpoint HbA1c <7 %
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.48 0.27 0.86 0.014
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.59 0.37 0.92 0.020
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.82 0.52 1.30 0.40
Endpoint HbA1c <7 % and no weight gain
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.47 0.26 0.88 0.018
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.72 0.45 1.15 0.17
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.79 0.49 1.29 0.35
HbA1c <7 %, no severe hypoglycemia, and no weight gain
 BMI <25 kg/m2 vs. BMI ≥35 kg/m2 0.47 0.26 0.88 0.018
 BMI 25–<30 kg/m2 vs. BMI ≥35 kg/m2 0.72 0.45 1.15 0.17
 BMI 30–<35 kg/m2 vs. BMI ≥35 kg/m2 0.79 0.49 1.29 0.35
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insulin doses were stabilized during the baseline periods 
prior to lixisenatide add-on treatment [5–7]. The stabiliza-
tion of insulin doses during the baseline periods may have 
also contributed to the fact that a patient’s BMI did not sig-
nificantly influence the frequency of hypoglycemia among 
lixisenatide treated patients.
Although not significant there was a trend observed in 
this analysis that having a greater baseline BMI is associ-
ated with a greater decrease in weight with lixisenatide 
add-on treatment. Thus, it is unlikely that normal weight 
T2DM patients are at risk for excessive weight loss when 
treated with lixisenatide add-on treatment. A smaller 
change in body weight was observed among patients in 
the subgroup with BMI <25 kg/m2 and may be related to 
that more of these patients were treated with sulfonylu-
rea, which can be associated with weight gain [7]. Due to 
the limitation of the small number of clinical trials and 
small sample sizes, whether the use of sulfonylurea vs. 
other OADs or metformin added on to basal insulin may 
impact the weight change among lixisenatide users may 
require additional future studies.
Limitations
There were trends for BMI to influence some efficacy 
measurements, which may be significant in studies with 
larger sample sizes (e.g. proportion of T2DM patients 
with HbA1c <7  % at trial endpoint at the unadjusted 
level). Inclusion of patients from the GetGoal-L-Asia 
trial in this analysis led to having an over representation 
of patients with lower BMIs, as the mean BMI of T2DM 
patients treated with lixisenatide in the GetGoal-Duo1, 
-L, and L-Asia trials were 32.0, 31.9, and 25.4  kg/m2, 
respectively. Additionally, patient data were extracted 
only from the lixisenatide treatment arms of the GetGoal 
trials. The results of this analysis may be further limited 
by the patient types and trial designs as evaluated in the 
GetGoal-Duo1, -L, and L-Asia trials. Furthermore, the 
impact of lixisenatide add-on treatment on blood pres-
sure was not evaluated in this analysis since detailed data 
on blood pressure were not reported in the original Get-
Goal-Duo1, -L, and -L-Asia trials [5–7].
Conclusions
The findings of these analyses of recent randomized clini-
cal trials suggest that lixisenatide may be a good treat-
ment option for optimizing glycemic control in T2DM 
patients unable to achieve their HbA1c glycemic target 
on basal insulin ±OADs, regardless of BMI.
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